- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07571954
Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy (iNFLOW-5)
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the Instroke 5F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke.
Prospective, single-arm, multi-centre study to evaluate the efficacy and safety of the iNstroke 5F thromboaspiration catheter in patients with acute ischaemic stroke
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This clinical investigation has been designed to evaluate the efficacy and safety of the iNstroke 5F aspiration catheter for its use in the treatment of LVO, with a view to comparing this product with standard therapy or with other similar products in a future pivotal clinical investigation.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Bordeaux, Frankrike
- CHU Bordeaux (H Pellegrin)
-
Hovedetterforsker:
- Xavier Barreau, Dr.
-
Ta kontakt med:
- Xavier Barreau, Dr
- Telefonnummer: +34 936724711
- E-post: clinica@ivascular.global
-
Lille, Frankrike
- CHU Lille
-
Ta kontakt med:
- Nicolas Bricout
- Telefonnummer: +34 936724711
- E-post: clinica@ivascular.global
-
Hovedetterforsker:
- Nicolas Bricout, Dr.
-
-
-
-
Andalusia
-
Málaga, Andalusia, Spania
- Hospital Regional Universitario de Málaga Carlos Haya
-
Ta kontakt med:
- María Teresa Díaz, Dr.
- Telefonnummer: +34 936724711
- E-post: clinica@ivascular.global
-
Hovedetterforsker:
- María Teresa Díaz, Dr.
-
-
Aragon
-
Zaragoza, Aragon, Spania
- Hospital Universitario Miguel Servet
-
Ta kontakt med:
- María Rosa Barrena
- Telefonnummer: +34 936724711
- E-post: clinica@ivascular.global
-
Hovedetterforsker:
- María Rosa Barrena, Dr.
-
-
Barcelona
-
Barcelona, Barcelona, Spania
- Hospital Clínico de Barcelona
-
Ta kontakt med:
- Jordi Blasco, Dr
- Telefonnummer: +34 936724711
- E-post: clinica@ivascular.global
-
Hovedetterforsker:
- Jordi Blasco, Dr.
-
-
Catalonia
-
L'Hospitalet de Llobregat, Catalonia, Spania
- Hospital Universitario Bellvitge
-
-
Galicia
-
Vigo, Galicia, Spania
- Hospital Álvaro Cunqueiro
-
Ta kontakt med:
- Carlos Manuel Rodriguez, Dr.
- Telefonnummer: +34 936724711
- E-post: clinica@ivascular.global
-
Hovedetterforsker:
- Carlos Manuel Rodriguez, Dr.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subjects aged ≥ 18 years.
- Subjects able to be treated (i.e., defined by groin puncture time) within 24 hours of symptom onset or last time seen well.
- Occlusion in a large or proximal medium vessel (M1, proximal M2, A2 or P2) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
- Baseline NIHSS score ≥ 6 assessed before the procedure.
- Pre-stroke mRS score ≤ 2.
- Subjects with an ASPECTS score ≥ 6.
- Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).
- France-specific inclusion criteria: As applicable under French law, subjects affiliated with a health social security scheme or equivalent.
Exclusion Criteria:
- Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
- Severe allergy to contrast media.
- Women of child-bearing potential.
- Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
- Medical history of thrombocytopenia (Platelets <100,000).
- Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
- Subjects with occlusions in multiple vessels.
- Subjects with cancer who have a life expectancy of less than 6 months.
- Pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.
- Severe sustained hypertension (systolic pressure >185 mm Hg or diastolic pressure >110 mm Hg). Note: If blood pressure can be successfully reduced and maintained at an acceptable level by administering the medication recommended by the ESO (European Stroke Organisation) in its guidelines (also IV infusion of antihypertensives), the subject may be included.
- Known or suspected cerebral vasculitis.
- Known renal insufficiency with creatinine ≥3 mg/dl or Glomerular Filtration Rate (GFR) <30 mL/min.
- Current participation in an interventional drug or device study that may confound the results of this study.
- Intracranial stenosis proximal to the occlusion.
- France-specific exclusion criteria: As applicable under French law, breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, or persons of legal age who are the subject of a legal protection measure.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Thromboaspiration using iNstroke 5F aspiration catheter
No comparator will be used as this is a traditional feasibility clinical investigation. The objective is to capture preliminary clinical performance, effectiveness and safety information to adequately plan an appropriate pivotal clinical investigation. |
Patients to undergo thromboaspiration with iNstroke 5F |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Recanalization Rate
Tidsramme: Intra-procedure
|
Recanalization rate with mTICI ≥2b in ≤3 revascularization passes using iNstroke Thrombus Extraction Aspiration Device aspiration catheter alone, or in conjunction with Stent Retriever |
Intra-procedure
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- iNFLOW-5
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .